Atossa Therapeutics (ATOS) Assets Average (2012 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Assets Average of $42.8 million for Q1 2026, down 41.88% year-over-year from $73.6 million in Q1 2025, and down 19.0% quarter-over-quarter from $52.8 million in Q4 2025.
Atossa Therapeutics (ATOS) Assets Average (2012 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Assets Average for 14 consecutive years, with $42.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 41.88% year-over-year to $42.8 million; the TTM figure through Mar 2026 stood at $42.8 million (down 41.88% YoY), while the FY2025 annual figure was $62.0 million, down 28.17% from the prior year.
- Assets Average slipped to $42.8 million in Q1 2026 per ATOS's latest filing, from $52.8 million in the prior quarter.
- Across five years, Assets Average topped out at $139.4 million in Q1 2022 and bottomed at $42.8 million in Q1 2026.
- Historically, Assets Average has averaged $94.6 million across 5 years, with a median of $93.7 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average soared 51.56% — and 2026, when it sank 41.88%.
- Atossa Therapeutics' Assets Average stood at $125.1 million in 2022, then slipped by 20.9% to $99.0 million in 2023, then decreased by 21.23% to $78.0 million in 2024, then sank by 32.26% to $52.8 million in 2025, then dropped by 19.0% to $42.8 million in 2026.
- Business Quant data shows ATOS's Assets Average at $42.8 million in Q1 2026, $52.8 million in Q4 2025, and $61.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 35.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.11 Mn |
| Mar 31, 2026 | 42.78 Mn |
| Dec 31, 2025 | 52.81 Mn |
| Sep 30, 2025 | 61.26 Mn |
| Jun 30, 2025 | 67.63 Mn |
| Mar 31, 2025 | 73.60 Mn |
| Dec 31, 2024 | 77.96 Mn |
| Sep 30, 2024 | 82.67 Mn |
| Jun 30, 2024 | 88.47 Mn |
| Mar 31, 2024 | 93.67 Mn |
| Dec 31, 2023 | 98.97 Mn |
| Sep 30, 2023 | 105.03 Mn |
| Jun 30, 2023 | 112.28 Mn |
| Mar 31, 2023 | 119.87 Mn |
| Dec 31, 2022 | 125.13 Mn |
| Sep 30, 2022 | 130.39 Mn |
| Jun 30, 2022 | 135.76 Mn |
| Mar 31, 2022 | 139.37 Mn |
| Dec 31, 2021 | 142.14 Mn |
| Sep 30, 2021 | 144.45 Mn |